Generic placeholder image

Current Pharmaceutical Biotechnology

Editor-in-Chief

ISSN (Print): 1389-2010
ISSN (Online): 1873-4316

Primary Sjogren’s Syndrome: Time for Prospective Cohorts

Author(s): Jacques-Eric Gottenberg and Xavier Mariette

Volume 13, Issue 10, 2012

Page: [2022 - 2025] Pages: 4

DOI: 10.2174/138920112802273128

Price: $65

Abstract

Many important clinical questions concerning primary Sjogren’s syndrome (pSS) remain, that can only be adequately addressed by prospective cohorts. Thus, a better knowledge of the clinical outcome, the course of disease activity and the risk factors of lymphoma requires the setting up of cohorts with biobanks. The homogeneous collection of clinical data, disease activity, patient-related outcome, and biological samples, including DNA, RNA and serum, is definitively mandatory to determine new biological prognostic factors and identify disease activity markers. Three large prospective cohorts have already started to enroll patients with pSS. This will be highly invaluable for scientists and clinicians to gain a better insight into the pathogenesis of pSS, as well as to identify prognostic markers and new therapeutic targets.

Keywords: Sjogren’s syndrome, prospective, cohort, disease activity, marker, clinical outcome, pathogenesis, therapeutic targets, clinical data, dryness symptoms, clinical disease, physical fatigue, prognostic factors, Sjogren’s International Collaborative Clinical Alliance (SICCA), clinical data.


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy